危重症患者高剂量阿米卡星治疗药物监测的列线图:群体药代动力学分析与给药方案模拟的启示
本研究在251例接受高剂量(30 mg/kg)阿米卡星静脉治疗的危重症患者中开展治疗药物监测,共获得488个浓度数据,建立二室群体药代动力学模型并进行蒙特卡洛模拟。以峰浓度/最低抑菌浓度≥8为疗效靶标,30 mg/kg方案对MIC<8 mg/L的达标概率>90%,对MIC=8 mg/L约为80%;对本地肺炎克雷伯菌的累积反应分数为63.5%,对敏感菌株为96.8%。按肾功能分层的列线图可指导给药间隔调整,以避免超过毒性最低浓度阈值2.5 mg/L。
要点
- 高剂量阿米卡星30 mg/kg对MIC<8 mg/L的肺炎克雷伯菌达标概率>90%,对MIC=8 mg/L约80%。
- 基于肌酐清除率和调整体重的列线图可个体化确定给药间隔,降低毒性风险。
- 对敏感肺炎克雷伯菌的累积反应分数达96.8%,但对本地菌群的累积反应分数仅63.5%。
核心结论
- 列线图辅助调整高剂量阿米卡星(30 mg/kg)给药间隔,可最大化危重症患者中敏感肺炎克雷伯菌感染的疗效与安全性目标达标率。
研究设计与样本
- 在251例接受高剂量(30 mg/kg)阿米卡星静脉治疗的危重症患者中开展治疗药物监测,共纳入488个阿米卡星浓度数据。
- 采用NONMEM® 7.5.1进行群体药代动力学建模和蒙特卡洛模拟,并以峰浓度/最低抑菌浓度≥8为疗效靶标评估达标概率。
主要发现
- 阿米卡星药代动力学最佳描述为二室模型,肌酐清除率和调整体重分别是清除率和中央室分布容积的显著协变量。
- 30 mg/kg阿米卡星对MIC<8 mg/L的达标概率>90%,对MIC=8 mg/L的达标概率约为80%。
- 该方案对肺炎克雷伯菌的累积反应分数为63.5%,对敏感菌株的累积反应分数为96.8%。
- 肌酐清除率<60 mL/min和≥60 mL/min患者的30 mg/kg列线图分别使约90%的虚拟患者在输注后20至32小时和6至32小时期间获得准确给药间隔。
关键数值与推荐
- 疗效靶标为峰浓度/最低抑菌浓度≥8。
- 毒性最低浓度阈值为2.5 mg/L,列线图用于避免超过该阈值。
- 列线图按肾功能分组(肌酐清除率<60 mL/min和≥60 mL/min)建立,以指导给药间隔。
临床怎么用
- 对接受高剂量阿米卡星(30 mg/kg)的危重症患者,可依据肌酐清除率和调整体重使用列线图确定给药间隔。
- 结合治疗药物监测和列线图,在确保疗效达标的同时避免浓度超过2.5 mg/L的毒性阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: This study evaluated the probability of pharmacokinetic/pharmacodynamic efficacy target attainment and developed a dosing interval identification nomogram to minimize toxicity risks of high-dose amikacin. METHODS: Therapeutic drug monitoring was performed in critically ill patients receiving high-dose (30 mg/kg) amikacin intravenously. Population pharmacokinetic modeling and Monte Carlo simulation were performed in NONMEM® 7.5.1. The probability of target attainment and the cumulative fraction of response for the local Klebsiella pneumoniae population were assessed using maximum concentration/minimum inhibitory concentration ≥ 8 as the efficacy target. Nomograms stratified by the renal function group were established to guide dosing intervals to avoid exceeding the toxicity minimum concentration threshold of 2.5 mg/L. RESULTS: A total of 251 patients with 488 amikacin concentrations were included. The amikacin pharmacokinetics was best described by a two-compartment model. The creatinine clearance and adjusted body weight were significant covariates for clearance and the central volume of distribution, respectively. Amikacin 30 mg/kg achieved a probability of target attainment > 90% for minimum inhibitory concentrations < 8 mg/L and around 80% for minimum inhibitory concentrations of 8 mg/L. This regimen showed a cumulative fraction of response of 63.5% for K. pneumoniae, while attaining a cumulative fraction of response of 96.8% for susceptible isolates. The 30-mg/kg nomograms in patients with creatinine clearance < 60 and ≥ 60 mL/min showed accurate dosing intervals with around 90% of virtual patients for the post-infusion period from 20 to 32 h and from 6 to 32 h, respectively. CONCLUSIONS: Nomogram-aided dosing interval adjustment of high-dose amikacin (30 mg/kg) maximized the efficacy and safety target attainment for critically ill patients with infections caused by susceptible K. pneumoniae.
引用
- Nguyen TC, Le DV, Nguyen HA, et al. Nomograms for Therapeutic Drug Monitoring of High-Dose Amikacin in Critically Ill Patients: Insights from a Population Pharmacokinetic Analysis and Dosing Simulation. Clin Pharmacokinet. 2026. PMID: 41661441. doi:10.1007/s40262-026-01621-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。